HBM Holdings Ltd.

03/22/2021 | Press release | Distributed by Public on 03/21/2021 17:44

VOLUNTARY ANNOUNCEMENT - DOSING OF FIRST PATIENT IN PHASE I CLINICAL STUDY OF NEXT-GENERATION ANTI-CTLA-4 ANTIBODY IN CHINA